GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. held its annual meeting on May 7, 2026, where stockholders elected eight directors, approved named executive officers’ compensation in an advisory vote, and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. Additionally, the Board of Directors appointed Rodney F. Hochman as the independent lead director and Anne T. Madden as chairperson of the Nominating and Governance Committee, effective the same day.

GE HealthCare Technologies Inc. acquired Intelerad for approximately $2.297 billion in cash, enhancing its Imaging segment with medical imaging software and digital workflow solutions. For Q1 2026, the company reported total revenues of $5.131 billion, a 7.4% increase year-over-year, but net income attributable to GE HealthCare decreased by 31.0% to $389 million, resulting in diluted EPS of $0.85. The decrease in net income was impacted by higher operating expenses and acquisition-related costs, despite improved cash from operating activities.

GE HealthCare reported Q1 2026 revenue of $5.1 billion, up 7.4% (2.9% organic), meeting the high end of expectations, driven by strong performance in Pharmaceutical Diagnostics and Imaging. However, profitability was impacted by a discrete PDx supplier issue and significant increases in memory chip, oil, and freight costs, leading to a 31.0% decrease in net income and a 2.0% decrease in Adjusted EPS. The company reaffirmed its full-year topline growth guidance but reduced its profit and Free cash flow outlook due to these inflationary pressures, while also completing the acquisition of Intelerad for $2.3 billion.